Deep Vein Thrombosis Global Market Report 2024

The deep vein thrombosis market has grown steadily in recent years. It will grow from $1.03 billion in 2023 to $1.07 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%.The expansion observed during the historical period can be attributed to several factors, including the increased specialization in vascular medicine, the influence of medical guidelines, a heightened focus on thrombosis prevention, advancements in clinical research and development, and an increased awareness leading to improved diagnosis. These factors collectively contributed to the growth witnessed in the specified timeframe.

The deep vein thrombosis market is expected to see steady growth in the next few years. It will grow to $1.26 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The anticipated growth in the forecast period can be attributed to various factors, including the growing aging population, a rising incidence of lifestyle diseases, an increased emphasis on preventive healthcare, the introduction of innovative therapies, and a focus on patient-centric care. Key trends expected in the forecast period encompass heightened awareness of risk factors, advancements in diagnosis techniques, innovations in treatment approaches, public health initiatives, and a notable emphasis on post-surgical prevention. These trends collectively contribute to the projected expansion in the specified timeframe.

The escalating demand for deep vein thrombosis (DVT) treatment is anticipated to fuel the expansion of the DVT market in the coming years. DVT treatment involves the administration of drugs, including anticoagulants, to mitigate the formation and enlargement of blood clots in individuals with deep vein thrombosis. The growing number of patients seeking DVT treatment signals an upsurge in the prevalence of deep vein thrombosis, necessitating the development of products for DVT diagnosis, prevention, and treatment. In February 2023, the Centers for Disease Control and Prevention (CDC) reported that an estimated 900,000 people in the United States could be affected annually by deep vein thrombosis, with 60,000 to 100,000 Americans succumbing to DVT or pulmonary embolism each year. Consequently, the rising demand for DVT treatment is a key driver propelling market growth.

The increasing incidence of obesity is poised to drive the growth of the deep vein thrombosis market. Obesity, a medical condition characterized by the accumulation of excess body fat, poses various health risks and complications. DVT treatment assumes a crucial role in managing obesity, given its status as an independent and moderate risk factor for venous thromboembolism (VTE), encompassing DVT and pulmonary embolism (PE). As of March 2023, the World Heart Federation disclosed that approximately 2.3 billion adults and children globally are either obese or overweight. With the prevailing obesity trend, projections indicate that the number of individuals living with obesity will reach 2.7 billion by 2025. Hence, the mounting prevalence of obesity stands as a driving force behind the growth of the deep vein thrombosis market.

The deep vein thrombosis market is witnessing a significant trend towards product innovation, with major industry players actively integrating advanced technologies to introduce novel products and fortify their market positions. A case in point is Penumbra Inc., a renowned US-based developer specializing in groundbreaking therapies. In January 2023, the company unveiled Lightning Flash, a state-of-the-art mechanical thrombectomy system meticulously engineered to tackle venous and pulmonary thrombus challenges. This innovative system showcases Penumbra's proprietary lightning-intelligent aspiration technology alongside cutting-edge dual clot detection algorithms. Specifically designed to swiftly address substantial blood clots, including venous thrombus and pulmonary emboli (PE), Lightning Flash equips physicians with a robust, high-torque catheter optimized for the efficient removal of clot burdens in both pulmonary arteries and the deep venous system. Notably, this system upholds an exemplary safety profile, underscoring its potential as a pivotal advancement in DVT treatment modalities.

Major players in the deep vein thrombosis (DVT) market are actively engaging in strategic partnerships to expedite the diagnosis of DVT and optimize their market profitability. This strategic approach underscores a growing interest in harnessing the capabilities of artificial intelligence (AI) and machine learning to enhance medical diagnostics, particularly in the swift and precise identification of DVT. A notable example occurred in November 2023 when UK-based ultrasound AI company ThinkSono Ltd. collaborated with US-based academic medical center NYU Langone Health. Together, they initiated the first clinical trial for an innovative AI-powered ultrasound software, known as the ThinkSono Guidance System. This technology aims to revolutionize the diagnosis of DVT by leveraging AI to potentially achieve faster, more precise, and cost-effective results compared to traditional techniques. The trial involves the utilization of the ThinkSono Guidance System alongside standard ultrasound scanning in patients with and without DVT. The performance of the two approaches will be rigorously assessed to confirm the accuracy of the ThinkSono system. The trial will also benefit from the participation of medical students from the NYU Grossman School of Medicine, contributing to the practical research curriculum.

In July 2021, Surmodics, a prominent US-based medical device and in-vitro diagnostic company, executed a strategic acquisition by acquiring Vetex Medical for $39.9 million. This acquisition aligns with Surmodics' broader strategy to expand its thrombectomy portfolio and bolster its position in the peripheral vascular market. With the addition of Vetex Medical to its portfolio, Surmodics gains access to valuable assets, including the ClotTriever system and other products in Vetex's pipeline, such as the Venous Solutions thrombectomy system. Vetex Medical, based in Ireland, specializes in developing medical devices for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). This strategic move positions Surmodics to offer an enhanced range of solutions, reinforcing its capabilities to address the complexities of DVT treatment and further solidifying its standing in the peripheral vascular market.

Major companies operating in the deep vein thrombosis market report are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Aspen Pharmacare Holdings Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Momenta Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, Laboratorios Farmacéuticos Rovi S.A., Cardinal Health Inc., Altimed Ltd., Teva Pharmaceutical Industries Ltd., Swiss Pharma Private Limited, Laurus Labs Limited, AstraZeneca PLC, Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Koninklijke Philips N.V., Arjo AB, DJO Global Inc., Zimmer Biomet Holdings Inc., Devon Medical Products LLC, ThermoTek USA Inc., Lonza Group AG, Pfizer Inc.

North America was the largest region in the deep vein thrombosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deep vein thrombosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of drugs utilized in the treatment of deep vein thrombosis include anticoagulants, inferior vena cava filters, and other therapeutic options. Anticoagulants, commonly referred to as blood thinners, are medications designed to prevent the formation of blood clots in the blood vessels. Treatment approaches for DVT encompass surgical interventions, pharmaceutical interventions, and other modalities. These treatments may be administered through various routes, including injectable, oral, and other methods. The distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Additionally, the end-users for these drugs span diverse healthcare settings such as hospitals, homecare, specialty clinics, and others.

The deep vein thrombosis market research report provides deep vein thrombosis market statistics, including deep vein thrombosis industry global market size, regional shares, competitors with a deep vein thrombosis market share, detailed deep vein thrombosis market segments, market trends and opportunities, and any further data you may need to thrive in the deep vein thrombosis industry. This deep vein thrombosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The deep vein thrombosis market includes revenues earned by entities by providing services related to treatment such as blood thinning medication, thrombolytic therapy, interventional radiology therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.